Related Experiment Video
Updated: Apr 4, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Scancell's vaccine SCIB1 could help to prevent recurrence of melanoma
1Scancell Limited, Department of Clinical Oncology, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK.
Abstract:
Interviewed by Ellen Clarke (Commissioning Editor, Future Science Group). Richard Goodfellow is Joint-CEO of Scancell Holdings plc, a public company listed on the London Stock Exchange. He has over 25 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company's flotation on the London Stock Exchange and successfully negotiated numerous deals. Goodfellow is also a founder of Paradigm Therapeutics, a Cambridge-based functional genomics company and is a former Director of Enact Pharma plc.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Vaccinations
Tumor Immunotherapy
Cancer Prevention
Some...
Cancer Prevention

